Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.

Context Mutations in the gene encoding Mediator complex subunit MED12 are dominant drivers of uterine fibroids (UFs) in women of diverse racial and ethnic origins. Previously, we showed that UF-linked mutations in MED12 disrupt its ability to activate cyclin C-CDK8/19 in Mediator. However, validation of Mediator kinase disruption in the clinically relevant setting of MED12-mutant UFs is currently lacking. Objective The objective of this study was twofold. First, to extend the ethnic distribution profile of MED12 mutations by establishing their frequency in UFs from Hispanic women of South Texas. Second, to examine the impact of MED12 mutations on Mediator kinase activity in patient-derived UFs. Methods We screened 219 UFs from 76 women, including 170 tumors from 57 Hispanic patients, for MED12 exon 2 mutations, and further examined CDK8/19 activity in Mediator complexes immunoprecipitated from MED12 mutation-negative and MED12 mutation-positive UFs. Results MED12 exon 2 mutations in UFs from Hispanic women are somatic in nature, predominantly monoallelic, and occur at high frequency (54.1%). We identified a minimal cyclin C-CDK8 activation domain on MED12 spanning amino acids 15 through 80 that includes all recorded UF-linked mutations in MED12, suggesting that disruption of Mediator kinase activity is a principal biochemical defect arising from these pathogenic alterations. Analysis of Mediator complexes recovered from patient UFs confirmed this, revealing that Mediator kinase activity is selectively impaired in MED12-mutant UFs. Conclusions MED12 mutations are important drivers of UF formation in Hispanic women of South Texas. MED12 mutations disrupt Mediator kinase activity, implicating altered CDK8/19 function in UF pathogenesis.

[1]  C. Cho,et al.  Current medical treatment of uterine fibroids , 2018, Obstetrics & gynecology science.

[2]  Min Ju Park,et al.  Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19 , 2018, The Journal of Biological Chemistry.

[3]  T. Falcone,et al.  Alternatives to hysterectomy: The burden of fibroids and the quality of life. , 2018, Best practice & research. Clinical obstetrics & gynaecology.

[4]  A. Al-Hendy,et al.  Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids† , 2017, Biology of Reproduction.

[5]  J. Carlow,et al.  Symptomatic Fibroid Management: Systematic Review of the Literature , 2017, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[6]  Juan Wu,et al.  Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma , 2017, Oncology letters.

[7]  B. Győrffy,et al.  Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer , 2017, Oncotarget.

[8]  Christopher C. Ebmeier,et al.  Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. , 2016, Cell reports.

[9]  Qiwei Yang,et al.  The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development , 2016, Reproductive Sciences.

[10]  L. Aaltonen,et al.  Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers , 2016, Proceedings of the National Academy of Sciences.

[11]  Min Ju Park,et al.  Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms , 2016, The Prostate.

[12]  M. Abbasi,et al.  The study of MED12 gene mutations in uterine leiomyomas from Iranian patients , 2016, Tumor Biology.

[13]  U. Surti,et al.  Med12 gain-of-function mutation causes leiomyomas and genomic instability. , 2015, The Journal of clinical investigation.

[14]  S. Bulun,et al.  Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution , 2015, Current opinion in obstetrics & gynecology.

[15]  F. Chibon,et al.  MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. , 2015, European journal of cancer.

[16]  A. Clark,et al.  Mediator kinase module and human tumorigenesis , 2015, Critical reviews in biochemistry and molecular biology.

[17]  S. Shahbazi,et al.  Somatic mutational analysis of MED12 exon 2 in uterine leiomyomas of Iranian women. , 2015, American journal of cancer research.

[18]  Elizabeth A Stewart,et al.  Clinical practice. Uterine fibroids. , 2015, The New England journal of medicine.

[19]  Jun Ye,et al.  High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients. , 2015, Genetic testing and molecular biomarkers.

[20]  M. Diamond,et al.  Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids , 2014, Molecular Genetics and Genomics.

[21]  C. Simón,et al.  Current understanding of somatic stem cells in leiomyoma formation. , 2014, Fertility and sterility.

[22]  Min Ju Park,et al.  Mutations in Exon 1 Highlight the Role of MED12 in Uterine Leiomyomas , 2014, Human mutation.

[23]  L. Aaltonen,et al.  Genomics of uterine leiomyomas: insights from high-throughput sequencing. , 2014, Fertility and sterility.

[24]  A. Clayton,et al.  Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. , 2014, American journal of obstetrics and gynecology.

[25]  Min Ju Park,et al.  Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. , 2014, Cell reports.

[26]  Hiroyuki Aburatani,et al.  Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome , 2014, International journal of cancer.

[27]  J. Coon,et al.  Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth , 2013, Proceedings of the National Academy of Sciences.

[28]  S. Bulun,et al.  Uterine fibroids , 2001, The Lancet.

[29]  T. Löning,et al.  MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups , 2012, International journal of cancer.

[30]  L. Aaltonen,et al.  Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer , 2012, British Journal of Cancer.

[31]  N. Yoo,et al.  Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors , 2012, International journal of cancer.

[32]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[33]  U. Surti,et al.  Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas , 2012, PloS one.

[34]  J. Segars,et al.  The estimated annual cost of uterine leiomyomata in the United States. , 2012, American journal of obstetrics and gynecology.

[35]  L. Aaltonen,et al.  MED12 exon 2 mutations are common in uterine leiomyomas from South African patients , 2011, Oncotarget.

[36]  L. Aaltonen,et al.  MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas , 2011, Science.

[37]  J. Massagué,et al.  A Smad action turnover switch operated by WW domain readers of a phosphoserine code. , 2011, Genes & development.

[38]  J. Bullerdiek,et al.  6p21 rearrangements in uterine leiomyomas targeting HMGA1. , 2010, Cancer genetics and cytogenetics.

[39]  N. Chegini,et al.  Proinflammatory and Profibrotic Mediators: Principal Effectors of Leiomyoma Development as a Fibrotic Disorder , 2010, Seminars in reproductive medicine.

[40]  L. Aaltonen,et al.  7q deletion mapping and expression profiling in uterine fibroids , 2005, Oncogene.